Semaglutide's Weight Loss Effects in Obesity

Prior treatment

• Weight change (self-reported) \> 5% in the past 3 months prior to screening
• Use of any medication for obesity indication in the past 3 months prior to screening.
• Use of immunosuppressants, corticosteroids, antidiarrheal drugs, antibiotics, probiotics, lipid-lowering medications, and/or other gastrointestinal motility drugs in the past 3 months prior to screening.

Other illness

• A history of endocrine-related overweight or obesity diagnoses, such as Cushing's syndrome.
• Known clinically significant gastric emptying abnormalities (e.g., severe diabetic gastroparesis or gastric outlet obstruction), gastrointestinal diseases, or surgical history.
• History of mental illness.
• History or family history of multiple endocrine neoplasia or medullary thyroid cancer, or calcitonin ≥ 6 pg/mL.
• History of cardiovascular disease.
• History of malignancy.
• Any other physiological, psychological, or other conditions deemed by the investigator as unsuitable for participation in the trial.

Lab values

• Use of antidiabetic medications in the past 3 months, or HbA1c ≥ 6.5%, or a history of Type 1 or Type 2 diabetes.
• Triglycerides ≥ 500 mg/dL (5.65 mmol/L) at screening.
• Abnormal liver function at screening, defined as alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \> 3\*ULN.
• Abnormal kidney function at screening, defined as estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.75m².

Other

• Thyroid dysfunction.
• Pregnancy or breastfeeding.

• Age 18-60 years
• BMI ≥ 30 kg/m²
• At least one self-reported unsuccessful attempt at lifestyle weight loss